|
|||||
|
|
| 索拉菲尼治疗肝癌肝移植术后肿瘤复发患者的疗效及安全性分析 | |
| 引用本文： | Li XH,Zhong KB,Liu Y,Yang DH,Zhou J. 索拉菲尼治疗肝癌肝移植术后肿瘤复发患者的疗效及安全性分析[J]. 南方医科大学学报, 2011, 31(9): 1608-1610 |
| 作者姓名： | Li XH Zhong KB Liu Y Yang DH Zhou J |
| 作者单位： | 南方医科大学南方医院肝胆外科,广东广州,501515 |
| 基金项目： | 广东省自然科学基金（10151051501000120） |
| 摘 要： | 目的探讨索拉菲尼治疗原发性肝细胞癌肝移植术后肿瘤复发患者的临床疗效和安全性。方法 10例肝移植术后肿瘤复发患者,确诊复发后即口服索拉菲尼400 mg,每日两次治疗(A组);8例未接受索拉菲尼治疗的肝癌肝移植术后肿瘤复发患者(B组);同期接受相同剂量的索拉菲尼治疗的肝癌患者25例(C组)。比较3组患者的带瘤生存时间、索拉菲尼的毒副作用及其他不良反应发生情况。结果 3组患者的带瘤生存时间分别为5~22个月(中位数10个月)、1~8个月(中位数4个月)和2~21个月(中位数4个月),三组之间整体间差异有统计学意义(K-M法,以log-rank检验,P=0.045)。两组肝移植患者没有发生急性排斥反应,但服用索拉菲尼组有1例患者因上消化道出血而死亡,服用索拉菲尼的两组患者不良反应发生率差异无统计学意义(P>0.05)。结论索拉菲尼能明显延长肝癌肝移植术后肿瘤复发患者的生存期,并不增加排斥反应发生率。 |
| 关 键 词： | 索拉菲尼 肝细胞癌 肝移植 肿瘤复发 |
Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients |
|
| Li Xiang-hong,Zhong Ke-bo,Liu Yan,Yang Ding-hua,Zhou Jie. Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients[J]. Journal of Southern Medical University, 2011, 31(9): 1608-1610 | |
| Authors: | Li Xiang-hong Zhong Ke-bo Liu Yan Yang Ding-hua Zhou Jie |
| Affiliation: | LI Xiang-hong,ZHONG Ke-bo,LIU Yan,YANG Ding-hua,ZHOU Jie Department of Hepatobiliary Surgery,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China |
| Abstract: | Objective To investigate the therapeutic effect and safety of Sorafenib in the treatment of tumor recurrence after orthotopic liver transplantation(OLT).Methods Between January,2009 and June,2011,10 patients with tumor recurrence after OLT were treated with Sorafenib(group A) and another 8 recipients received no Sorafenib treatment(group B);25 patients with hepatocellular carcinoma(HCC) also received Sorafenib treatment(group C).The tumor-bearing survival time,adverse effect and toxicity associated with sor... |
| Keywords: | sorafenib hepatocellular carcinoma liver transplantation tumor recurrence |
| 本文献已被 CNKI 万方数据 PubMed 等数据库收录！ | |